返回 
加入收藏
非奈利酮联合肾康宁胶囊治疗脾肾阳虚兼血瘀证DKD患者的疗效
x
请在关注微信后，向客服人员索取文件
| 篇名： | 非奈利酮联合肾康宁胶囊治疗脾肾阳虚兼血瘀证DKD患者的疗效 |
| TITLE： | Efficacy of finerenone combined with Shenkangning capsules in diabetic kidney disease patients with spleen-kidney yang deficiency and blood stasis syndrome |
| 摘要： | 目的 探讨非奈利酮联合肾康宁胶囊治疗脾肾阳虚兼血瘀证糖尿病肾脏疾病（DKD）患者的临床疗效及对肾脏的保护作用，并评价其安全性。方法回顾性收集2024年5月至2025年8月于我院肾病科及内分泌科收治的150例DKD且经中医辨证符合脾肾阳虚兼血瘀证患者的资料，根据治疗方案分为对照组（n＝74）和观察组（n＝76）。两组患者均接受DKD标准化治疗，在此基础上，对照组患者接受非奈利酮片，观察组患者在对照组治疗基础上加用肾康宁胶囊，两组均连续治疗3个月。比较两组患者治疗3个月后的临床疗效，治疗前及治疗3个月后的中医证候评分（TCMSS）、肾功能指标[血清肌酐（Scr）、胱抑素C（CysC）、β2微球蛋白（β2-MG）]、蛋白尿指标[尿白蛋白/肌酐比值（UACR）、24h尿蛋白定量（24hUTP）]、炎症指标[超敏C反应蛋白（hs-CRP）、白细胞介素-6（IL-6）]及不良反应发生情况。结果治疗3个月后，观察组患者的总有效率显著高于对照组（P＜0.05）；两组患者的TCMSS、Scr、CysC、β2-MG、UACR、24hUTP、hs-CRP及IL-6水平均显著低于同组治疗前（P＜0.05），且观察组上述指标均显著低于对照组（P＜0.05）。两组患者的不良反应总发生率比较，差异无统计学意义（P＞0.05）。结论非奈利酮联合肾康宁胶囊可改善脾肾阳虚兼血瘀证DKD患者的中医证候，减少蛋白尿并改善肾功能及炎症相关指标，且未增加不良反应发生风险。 |
| ABSTRACT： | OBJECTIVE To investigate the clinical efficacy and renoprotective effects of finerenone combined with Shenkangning capsules in diabetic kidney disease （DKD） patients with spleen-kidney yang deficiency and blood stasis syndrome， and to evaluate the safety.METHODS Clinical data of 150 patients with DKD conforming to the traditional Chinese medicine （TCM） syndrome differentiation of spleen-kidney yang deficiency and blood stasis syndrome were retrospectively collected from the departments of nephrology and endocrinology of our hospital from May 2024 to August 2025. Based on the treatment regimen received， patients were divided into a control group （ n ＝74） and an observation group （ n ＝76）. All patients in both groups received standardized treatment for DKD. In addition， the control group received Finerenone tablets， whereas the observation group received Shenkangning capsules combined with the same regimen as the control group. Both groups were treated continuously for 3 months. The clinical efficacy was evaluated and compared between the two groups after the 3-month treatment period. Additionally， TCM syndrome score （TCMSS）， renal function parameters [serum creatinine （Scr）， cystatin C （CysC）， and β 2 -microglobulin （β 2 -MG）]， proteinuria markers[urinary albumin-to-creatinine ratio （UACR）， 24 hour urinary total protein （24 hUTP）]， inflammatory markers[high-sensitivity C-reactive protein （hs-CRP）， interleukin-6 （IL-6）] before and after 3 months of continuous treatment as well as the incidence of adverse reactions were compared between the two groups.RESULTS After 3 months of treatment，the total effective rate in the observation group was significantly higher than in the control group （ P ＜0.05）. In both groups， the TCMSS， Scr， CysC， β 2 -MG， UACR， 24 hUTP， hs-CRP， and IL-6 levels were significantly lower than those before treatment in the same group （ P ＜0.05）， and all the above indicators in the observation group were significantly lower than those in the control group （ P ＜0.05）. There was no statistically significant difference in the overall incidence of adverse reactions between the two groups （ P ＞0.05）.CONCLUSIONS The combination of finerenone and Shenkangning capsules improved TCM syndromes，reduced proteinuria， and improved renal function and inflammation-related indicators in DKD patients with spleen-kidney yang deficiency and blood stasis syndrome， without increasing the risk of adverse reactions. |
| 期刊： | 2026年第37卷第18期 |
| 作者： | 王阳洋；张亚琦；王渭琴；尹骁翔；梅建锋 |
| AUTHORS： | WANG Yangyang，ZHANG Yaqi，WANG Weiqin，YIN Xiaoxiang，MEI Jianfeng |
| 关键字： | 糖尿病肾脏疾病;脾肾阳虚兼血瘀证;非奈利酮;肾康宁胶囊;疗效;肾功能;安全性 |
| KEYWORDS： | diabetic kidney disease;spleen-kidney yang deficiency and blood stasis syndrome;finerenone;Shenkangning capsules;Efficacy;Renal function;Safety |
| 阅读数： | 1 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
